Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06680752 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 1 of 3 sitesv4
  2. Study sites: 2 to 3
    • Start date changed from estimate of May 2025 to May 20, 2025
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Mar 2025 to May 2025
    • Study sites: 0 to 2
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase I/2, interventional, open-label, multicenter study to assess the safety and efficacy of ARD103 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
Trial Details
NCT Number NCT06680752
Lead Sponsor ARCE Therapeutics, Inc.
Conditions
(from sponsor)		 Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome)
Related terms Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute
Enrollment 49 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov